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Genetic causes of hypopituitarism
Katherine Parkin1, Ritika Kapoor2, Ravindra Bhat3,4, Anne Greenough4,5,6
A b s t r a c t
Hypopituitarism in neonates is rare, but has life-threatening complications 
if untreated. This review describes the features of hypopituitarism and the 
evidence for which infants in whom a genetic cause should be suspected. 
Importantly, neonates are often asymptomatic or present with non-specific 
symptoms. Hypopituitarism can be due to abnormal gland development as 
a result of genetic defects, which result from mutations in gene coding for 
transcription factors which regulate pituitary development. The mutations 
can be divided into those causing isolated hypopituitarism or those causing 
syndromes with associated hypopituitarism. The latter involve mutations in 
transcription factors which regulate pituitary, as well as extra-pituitary de-
velopment. There is a paucity of evidence as to which patients should be in-
vestigated for genetic mutations, but detailed clinical and biochemical phe-
notyping with magnetic resonance imaging of the pituitary gland could help 
target those in whom genetic investigations would be most appropriate. 
Key words: congenital hypopituitarism; genetic defects, magnetic 
resonance imaging.
Introduction
Hypopituitarism in neonates is rare. It affects between 1 in 4000 to 
1 in 10,000 live births [1] and can manifest as a partial or complete insuf-
ficiency of pituitary hormone secretion. It is, however, a serious condition 
with life-threatening complications if untreated. Although 52% of neo-
nates with hypopituitarism present postnatally with associated compli-
cations, only 23% are diagnosed in the neonatal period [2]. Neonates are 
often asymptomatic or present with non-specific symptoms. This review 
focuses on the genetic causes of hypopituitarism including those caus-
ing isolated pituitary problems and those with extra-pituitary manifes-
tations and assesses the evidence base to determine which infants in 
whom a genetic cause should be suspected and investigated.  
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Presentation
Congenital hypopituitarism may present with 
a  loss of function of a  single pituitary hormone, 
commonly isolated growth hormone deficiency 
(IGHD), or with two or more pituitary hormone de-
ficiencies (multiple pituitary hormone deficiency – 
MPHD). It may be part of an underlying syndrome 
with abnormalities of extra-pituitary structures 
such as the eyes and forebrain which have a com-
mon embryological origin to the pituitary gland. 
Neonates may often be asymptomatic and then de-
velop abnormal signs due to evolving hormone de-
ficiencies. Congenital hypopituitarism may present 
at birth, but is difficult to diagnose in the neonatal 
period, as the signs may be non-specific, including 
lethargy, apnoea, poor weight gain and feeding 
problems and the clinical presentation depends on 
the pituitary hormone deficiencies present.
Growth failure due to GHD usually presents 
after the first year after birth, though may be 
present in infancy in severe GHD [3]. Severe hypo-
glycaemia, at or soon after birth, is a uncommon 
presentation and results from adrenocorticotropic 
(ACTH) deficiency or lack of growth hormone (GH) 
secretion [4]. Micropenis, defined as a  stretched 
penis length of less than 2.5 cm, may be present 
and is caused by low luteinizing hormone (LH) se-
cretion which is responsible for maintaining fetal 
testosterone production. Bilateral undescended 
testis may also be present as the fetal testicular 
descent is dependent on LH. Less specific signs 
of hypopituitarism include neonatal hepatitis and 
cholestatic jaundice [5]. In one study, jaundice 
was found to be the most common presentation 
in 35% of those presenting with hypopituitarism 
as neonates or young infants [6]. The pathophys-
iology of liver damage in hypopituitarism is sug-
gested to be due to insufficient glucocorticoid 
and thyroid hormones [7]. In patients with thyroid 
stimulating hormone (TSH) deficiency, hyperbili-
rubinaemia can be associated with temperature 
instability [8]. The most common electrolyte im-
balance is hyponatraemia, which is related to in-
adequate levels of ACTH and TSH. In those with 
posterior pituitary abnormalities, diabetes insipi-
dus is often the key presentation, due to lack of 
antidiuretic hormone (ADH). 
Genetic abnormalities
Mutations in any of the genes involved in pi-
tuitary development may result in congenital 
hypopituitarism leading to deficiency in one or 
more pituitary hormones. Genetic abnormalities, 
however, are only identified in 5–10% of those 
with congenital hypopituitarism, but it is esti-
mated that a  further 5–30% of individuals with 
a first-degree relative with the disorder possess 
a genetic mutation yet to be identified [8]. Muta-
tions in gene coding for growth hormone (GH1) 
and gene coding the growth hormone releasing 
hormone receptor (GHRHR) are known to cause 
idiopathic growth hormone deficiency (IGHD). 
Mutations in various genes which encode tran-
scription factors related to pituitary development 
have been associated with varying degrees of hy-
popituitarism (Table I). In one study, 13% of indi-
viduals had a mutation in one of five commonly 
mutated genes (POU1F1, PROP1, LHX3, LHX4, and 
HESX1), rising to 52% of individuals in familial 
cases of multiple pituitary hormone deficiency 
(MPHD) [9]. The prevalence of genetic mutations 
varies worldwide, such that PROP1 mutations ac-
count for the majority of genetic MPHD in Europe, 
but are much less common in Asians [10]. We 
have focused on the role of the main transcrip-
tion factors involved in pituitary development 
and mechanisms underlying hypopituitarism and 
accompanying phenotypes. 
Table I. Transcription factors related to pituitary 
development
HESX1 Homeobox expressed in embryonic 
stem cells 1
SOX2/SOX3 Sex determining region Y box 2/3
LHX3, LHX4 LIM/homeobox protein
PROP1 Homeobox protein prophet of PIT1
POU1F1 Pituitary specific positive 
transcription factor 1
PITX Paired-like homeodomain 1
GLI3, GLI2 Zinc finger protein
OTX2 Orthodenticle homeobox 2
ARNT2 Aryl hydrocarbon receptor nuclear 
translocator 2
IGSF1 Immunoglobulin superfamily 1
FGF8 Fibroblast growth factor 8
FGFR1 Fibroblast growth factor receptor 1
PROKR2, PROK2 Prokineticin receptor 2
CHD7 Chromodomain helicase DNA 
binding protein 7
WDR11 WD repeat containing protein 11
NFKB2 Nuclear factor NFkB p100 subunit
TCF7L1) Transcription factor 7 like 1
PAX6 Paired box protein pax 6
IFT72 Intraflagellar transport 72
GPR161 G protein coupled receptor 161
CDON Cell adhesion molecule related/
down regulated by oncogenes
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PROP1
PROP1, located on chromosome 5q, encodes 
for a  paired-like homeodomain protein essential 
for HESX1 repression and POU1F1 expression [10, 
11]. It is essential for the development of most 
types of anterior pituitary cells, therefore, patients 
can present with deficiency of all hormones se-
creted by the anterior pituitary [3]. In humans, 
at least 25 mutations in PROP1 (both homo- and 
heterozygous) have been described and these are 
responsible for the majority of MPHDs [12]. The 
most frequent mutations are a  two-base-pair 
deletion within exon 2, causing a  frameshift in 
codon 101 (301-302delAG) and a  one-base-pair 
deletion in codon 50 (150delA). Both result in 
the production of a  termination codon and ear-
ly cessation of protein sequencing [10, 11]. Mis-, 
nonsense and splicing error mutations have also 
been found [10]. Recessive PROP1 mutations of-
ten present with GH deficiency early in life and 
may have the phenotypic presentation of gonad-
otrophin deficiency (micropenis, cryptorchidism, 
lack of puberty and/or infertility). TSH and ACTH 
are often normal in early life, but deficiencies in 
these hormones often evolve with increasing age 
emphasising the need for continuous monitoring.
POU1F1
POU1F1 is another pituitary-specific transcrip-
tion factor, responsible for differentiation of soma-
to-lactotrophs and thyrotophs. These cells secrete 
GH, PRL and TSH. POU1F1 may also be involved in 
autoregulation of expression, as its binding sites 
have been found on the POU1F1 gene. Approxi-
mately 8% of MPHD and isolated GH cases are due 
to mutations in this gene [13]. Since first being 
described, 38 mutations have been reported; most 
are autosomal recessive, although five dominant 
mutations have been found [11, 14, 15]. A sibling 
case suggests that isolated mutations in the short 
isoform of POU1F1 might be sufficient for induc-
tion of POU1F1 related combined pituitary hor-
mone deficiency [16]. As in PROP1 mutations, indi-
viduals may present with GH deficiency including 
early growth failure and failure to thrive. The age 
at presentation of TSH deficiency is highly variable 
[14, 17] and cases with normal TSH levels have 
been reported [13]. Indeed, the pituitary gland may 
be normal or hypoplastic on MRI [11, 13]. 
LHX3 and LHX4
LHX3 and LHX4 are involved in the complex ge-
netic cascade resulting in pituitary development, 
critical for development of Rathke’s pouch. LHX4 
is essential for pituitary development and motor 
neuron specification in mammals [18]. Extra-pi-
tuitary expression has been documented in other 
regions of the brain and spinal cord. Mutations in 
genes encoding for these transcription factors are 
rare. Seven different mutations in LHX3, including 
base pair deletions, mutations and even one case 
of whole gene deletion have been documented 
[19]. Mutations in LHX3 present similarly to muta-
tions in PROP1 with GH, PRL, TSH and/or LH/FSH 
deficiency. Rarely, ACTH deficiency has also been 
described. In addition to pituitary abnormalities, 
patients present with a short, rigid cervical spine, 
limited head rotation and trunk movement [14, 
19]. Bilateral sensorineural hearing loss has also 
been documented in some cases [19]. Other ab-
normalities include cervical vertebral malforma-
tions (rigid neck, scoliosis), mild developmental 
delay and moderate sensorineural hearing loss 
[20]. Heterozygous LHX3 mutations may lead 
to a  mild phenotype of combined pituitary hor-
mone deficiency [21]. Sonic hedgehog (SHH) is 
an essential morphogenetic signal which dictates 
cell fate decision in several organs in mammals. 
In vitro data suggest that SHH is required to spec-
ify LHX3+/LHX4+ Rathe’s Pouch (RP) progenitor 
identity. In mouse embryos, conditional deletion 
of SHH in the anterior hypothalamus results in 
a  fully penetrant phenotype characterised by 
complete arrest of RP development with lack of 
LHX3/LHX4 expression and total loss of pituitary 
development [22]. In one case of LHX4 mutation, 
a fully penetrant, dominant mutation caused de-
fective splicing. An magnetic resonance imaging 
(MRI) showed anterior pituitary hypoplasia, an ec-
topic posterior pituitary and a shortened pituitary 
stalk. The three-generation family all presented 
with short stature, some with an abnormal sel-
la turcica and Chiari malformation with pointed 
cerebellar tonsils [23]. In another case, who pre-
sented with severe respiratory distress and hypo-
glycaemia soon after birth, had multiple pituitary 
hormone deficiencies. MRI demonstrated a  hy-
poplastic anterior pituitary, an ectopic posterior 
lobe, a poorly developed sella turcica and Chiari 
malformation. Sequence analyses of the LHX4 
gene identified a  heterozygous missense muta-
tion (P366T) in exon 6, which was present in the 
LIM4 specific domain [18]. Screening of 136 pa-
tients with congenital hypopituitarism associated 
with malformations of brain structures, pituitary 
stalk or posterior pituitary gland demonstrated 
a novel dysfunctional LHX4 mutation (p.Thr99fs) 
which was responsible for the patient’s pheno-
type [24]. In another study, heterozygous mis-
sense mutations in LHX4 resulting in the substi-
tution of amino acids resulted in GH deficiency, 
+/– reductions in LH, TSH, FSH or ACTH and aber-
rant pituitary morphology [25]. Screening of 417 
unrelated patients with isolated growth hormone 
deficiency or combined protein deficiency associ-
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ated with ectopic posterior pituitary and/or sella 
turcica anomalies demonstrated seven heterozy-
gous variations in LHX4 [26].
Homeobox expressed in ES cells 1 (HESX1) 
and sry-type HMG box (SOX) genes in  
septo-optic dysplasia
Septo-optic dysplasia, although rare, is the 
most common congenital cause of hypopituitar-
ism, encompassing any combination of two of the 
triad: optic nerve hypoplasia, hypopituitarism and 
midline structural abnormalities [1]. Its incidence 
is reported to be 1 in 10,000 live births. Hypopi-
tuitarism affects 62% of those with the condition 
and its severity may be predicted by the degree of 
midline structural abnormalities. Several genetic 
mutations have been demonstrated to result in 
various forms of the condition [27].
HESX1, a  transcriptional repressor, regulates 
some of the earliest stages of pituitary develop-
ment. It is expressed during gastrulation in the 
region which develops into the forebrain, after 
which it is restricted to expression in the ventral 
diencephalon and the region of the oral ectoderm 
which forms Rathke’s pouch [14]. It has a role in 
optic nerve formation [3, 14]. Null HESX1 mice 
have pituitary hypoplasia, micro- or anophthal-
mia and agenesis of midline forebrain derivatives; 
a similar phenotype to that of the human condi-
tion septo-optic dysplasia [14, 28]. A  large study 
confirmed that the overall expression of HESX1 
mutations in SOD is low [9, 29]. Another study 
looked at the prevalence of pituitary hormone 
abnormalities with optic nerve hypoplasia (with 
or without midline brain abnormalities), howev-
er, found that the prevalence may be as high as 
72% [30]. Several different mutations have been 
documented; which vary in the extent of hormone 
deficiency [14]. Isolated GH deficiency to MPHD 
have been described with or without optic nerve 
hypoplasia and or mid-line brain abnormalities 
[14, 31]. Heterozygous mutations are milder than 
the bi-allelic type.
SOX2 and -3 are SRY-related HMG box tran-
scription factors may be responsible for maintain-
ing pituitary progenitor cells and their function 
[12]. Heterozygous mutations in SOX2 genes are 
associated with developmental eye abnormalities 
such as anophthalmia and microphthalmia. Oe-
sophageal abnormalities, urogenital defects, de-
velopmental delay and sensorineural hearing loss 
have also been associated with SOX2 mutations, 
as SOX2 plays an important role in the develop-
ment of the eye, forebrain, gastrointestinal tract 
and urogenital systems. The phenotype usually 
includes anterior pituitary hypoplasia on MRI scan 
and hypogonadotrophic hypogonadism. GHD has 
been described in a single case [32]. SOX3 is lo-
cated on the X-chromosome, therefore, mutations 
in SOX3 primarily affect males. Under and over 
exposure of the gene has been involved in caus-
ing X-linked hypopituitarism, resulting in varying 
degrees of hypopituitarism, mid-line brain abnor-
malities and learning disabilities
SHH and GLI2 in holoprosencephaly (HPE)
HPE encompasses a number of structural mid-
line forebrain abnormalities, some of which are 
fatal in utero. The most severe form is alobar 
HPE, whereby the forebrain fails to develop into 
two hemispheres. This is often accompanied 
by midline facial deformities. The milder forms, 
which are compatible with life, can present with 
defective facial features such as hypotelorism 
and one nostril, but can also present with more 
distal manifestations such as polydactyly. Due to 
the location of the hypothalamus and pituitary 
gland as midline structures, their formation may 
be affected in HPE, resulting in hypopituitarism. 
Deficient ADH production may occur in as many 
as 70% of affected patients [33]. Other variations 
of hypopituitarism presentation are isolated GH 
deficiency, MPHD or increasing manifestation of 
hormone deficiencies with age. Genetic mutations 
in the sonic hedgehog (SHH) gene are known to 
cause HPE and have also been linked to pituitary 
gland formation [34]. SHH is expressed in midline 
structures early in development, as well as con-
trolling distal limb development. It is expressed in 
the ventral diencephalon and oral ectoderm, prior 
to formation of Rathke’s pouch. SHH signalling, 
together with FGF8/10 (also known to cause HPE 
when mutated), regulate LHX3 signalling.
The GLI2 transcription factor, along with GLI1 
and GLI3, is essential for mediating SHH signal-
ling [35–37]. In mice, whilst GLI1 and GLI3 are un-
essential, GLI2 has been shown to be the major 
transcription factor required for pituitary develop-
ment [38]. GLI2 is expressed in the same locations 
as SHH during pituitary development. Mutations 
in this gene phenotypically present with HPE-like 
features: polydactyly and hypopituitarism [35, 39]. 
GLI2 mutations, although often found in GHD with 
normal brain morphology [40], can cause anterior 
pituitary hypoplasia and an absent posterior pitu-
itary. GLI2 mutants have been shown to affect the 
proliferation and specialization of cells in the pitu-
itary gland, but not affect its formation. Therefore, 
the absence of the posterior pituitary is hypothe-
sized to be due to its relationship with SHH [41].  
GLI3 and Pallister-Hall syndrome
GLI3 autosomal dominant mutations causes 
Pallister-Hall syndrome [42]: a rare condition char-
acterized by polydactyly, bifid epiglottis, hypotha-
lamic hamartoma, pituitary dysfunction and an 
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imperforate anus. The endocrine abnormalities 
can range from isolated GH deficiency to MPHD. 
De novo mutations are more severe in presenta-
tion than inherited mutations [43].
FGF8 and FGFR1 in Kallmann syndrome  
and idiopathic hypogonadotrophic 
hypogonadism (IHH)
Kallmann syndrome is one of a group of condi-
tions known as hypogonadotropic hypogonadism 
(HH), whereby gonadal development and function-
al activity is impaired by reduced gonadotropin se-
cretion, associated with reduced or lack of sense 
of smell. Mutations in FGF8 and FGFR1 have been 
found in 10% of patients with Kallmann syndrome 
and 7% of those with idiopathic hypogonadotrop-
ic hypogonadism [44]. They are believed to control 
release of gonadotropin releasing hormone, which 
stimulates LH and FSH release from the pituitary 
gland. Clinically, HH presents with failure of pu-
bertal onset with low levels of sex steroids and 
gonadotrophins. Milder phenotypes may include 
secondary amenorrhea, delay of puberty onset or 
adult onset of hypogonadotrophic hypogonadism. 
Although previously mutations in these genes 
were only thought to cause Kallmann syndrome/ 
IHH, more recent studies have shown that muta-
tions in these genes can also cause a wider phe-
notype of MPHD or SOD [45]. Mutations in several 
other genes are also impacted in the pathogene-
sis of Kallmann syndrome and IHH [46]. 
Investigation of suspected hypopituitarism
In a  neonate with suspected hypopituitarism, 
biochemical evaluation of the hypothalamic-pi-
tuitary axis should be undertaken to evaluate for 
and define the extent of pituitary hormone defi-
ciencies. As cortisol deficiency can be life-threat-
ening, evaluation of ACTH deficiency by a  short 
Synacthen test (sensitivity of 80%) is essential. 
TSH deficiency can be identified by low serum free 
thyroxine (fT4) and normal/ low serum TSH. GH 
stimulation tests to diagnose GHD are undertaken 
after a year of age, although low GH levels during 
earlier spontaneous hypoglycaemia may suggest 
GHD. Hypogonadotrophic hypogonadism may be 
suspected in males with micropenis with or with-
out bilateral undescended testes. Baseline low 
gonadotrophins with GnRH and HCG (in males) 
stimulation tests in infancy can help determine 
gonadotrophin deficiency. Diabetes insipidus is 
diagnosed by the presence of hypernatremia with 
raised plasma osmolality and concurrent low urine 
osmolality. MRI imaging of the brain and pituitary 
gland should be undertaken in any neonate with 
suspected hypopituitarism to evaluate the size of 
the anterior pituitary gland, the presence and lo-
cation of posterior pituitary gland, the presence 
of midline (corpus callosum/ septum pellucidum) 
and other brain (such as HPE) abnormalities and 
the presence and size of the optic nerves.
Although several genetic causes of hypopi-
tuitarism have been identified by novel genetic 
technologies, the yield of genetic testing in hy-
popituitarism remains low. Detailed clinical and 
biochemical phenotyping along with MRI imag-
ing of the pituitary gland may help identify those 
where genetic testing may be helpful. For exam-
ple. PROP1 mutation needs to be considered in 
a patient with multiple pituitary hormone defi-
ciency with an intact pituitary stalk and poste-
rior pituitary [47]. In patients with septo-optic 
dysplasia, a HESX1 mutation should be investi-
gated, although it has been recently shown that 
HESX1 mutations cause variable clinical features 
in patients and can also be seen in patients 
without septo-optic dysplasia [48]. Genetic test-
ing is also likely to be beneficial in familial cases 
of hypopituitarism. Genetic analysis, however, is 
unlikely to be helpful in sporadic cases of hypo-
pituitarism in Western European populations in 
the absence of specific MRI and extra-pituitary 
abnormalities [49, 50].
Management of an infant identified with hy-
popituitarism requires a  multi-disciplinary team 
approach in a  tertiary paediatric endocrinology 
centre and includes adequate replacement of hor-
mone deficiencies and management of associated 
conditions and/or neurodevelopmental delay. Life-
long monitoring for adequacy of hormone replace-
ment and evaluation of evolving hormone defi-
ciencies is indicated. Genetic counselling should 
be offered to parents in whose infant a  genetic 
cause has been identified.
Conclusions
Due to the serious complications associated 
with untreated disease, hypopituitarism should be 
considered in neonates presenting with hypogly - 
caemia, hypogonadism or unexplained jaundice. 
Many factors can cause congenital hypopituita-
rism: although rare, genetic causes of hypopi-
tuitarism are becoming better understood. The 
syndromes presenting with hypopituitarism asso-
ciated with extra-pituitary abnormalities are more 
easily characterized and genetic causes more like-
ly. For PROP1 it is important to consider the geo-
graphical origin of the patient as this mutation is 
more frequent in some ethnic groups [49]. MRI 
imaging of the brain and pituitary gland, along 
with hormonal profile and presence of specific ex-
tra-pituitary manifestations can help target specif-
ic genetic testing in patients with hypopituitarism. 
Similarly, this should be undertaken in infants with 
suspected hypopituitarism due to a positive family 
history. Despite the identification of an increased 
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number of genetic causes of isolated or multiple 
pituitary deficiencies it should be appreciated that 
the etiology of most (80–90%) congenital causes 
of hypopituitarism remain unsolved [12].
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